Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.

CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy

Open access

Abstract

Cancer immunotherapy restores or enhances the effector function of CD8+ T cells in the tumour microenvironment 1,2. CD8+ T cells activated by cancer immunotherapy clear tumours mainly by inducing cell death through perforin-granzyme and Fas-Fas ligand pathways 3,4. Ferroptosis is a form of cell death that differs from apoptosis and results from iron-dependent accumulation of lipid peroxide 5,6. Although it has been investigated in vitro 7,8, there is emerging evidence that ferroptosis might be implicated in a variety of pathological scenarios 9,10. It is unclear whether, and how, ferroptosis is involved in T cell immunity and cancer immunotherapy. Here we show that immunotherapy-activated CD8+ T cells enhance ferroptosis-specific lipid peroxidation in tumour cells, and that increased ferroptosis contributes to the anti-tumour efficacy of immunotherapy. Mechanistically, interferon gamma (IFNγ) released from CD8+ T cells downregulates the expression of SLC3A2 and SLC7A11, two subunits of the glutamate-cystine antiporter system x c-, impairs the uptake of cystine by tumour cells, and as a consequence, promotes tumour cell lipid peroxidation and ferroptosis. In mouse models, depletion of cystine or cysteine by cyst(e)inase (an engineered enzyme that degrades both cystine and cysteine) in combination with checkpoint blockade synergistically enhanced T cell-mediated anti-tumour immunity and induced ferroptosis in tumour cells. Expression of system x c- was negatively associated, in cancer patients, with CD8+ T cell signature, IFNγ expression, and patient outcome. Analyses of human transcriptomes before and during nivolumab therapy revealed that clinical benefits correlate with reduced expression of SLC3A2 and increased IFNγ and CD8. Thus, T cell-promoted tumour ferroptosis is an anti-tumour mechanism, and targeting this pathway in combination with checkpoint blockade is a potential therapeutic approach.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-019-1170-y

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Cited by

See all 2,880

Metadata

Authors
Wang, W., Green, M., Choi, J. E., Gijón, M., Kennedy, P. D., Johnson, J. K., Liao, P., Lang, X., Kryczek, I., Sell, A., Xia, H., Zhou, J., Li, G., Li, J., Li, W., Wei, S., Vatan, L., Zhang, H., Szeliga, W., Gu, W., Liu, R., Lawrence, T. S., Lamb, C., Tanno, Y., Cieslik, M., Stone, E., Georgiou, G., Chan, T. A., Chinnaiyan, A., & Zou, W.
Affiliations
  • University of Michigan (US)
  • Cayman Chemical (United States) (US)
  • Herbert Irving Comprehensive Cancer Center (US)
  • The University of Texas at Austin (US)
  • Memorial Sloan Kettering Cancer Center (US)
  • Howard Hughes Medical Institute (US)
Corresponding author
Zou, Weiping
Venue
Nature
Published
2019-05
Volume
569
Issue
7755
Pages
270-274
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W2943793201
Cited by
2,880
References
30
Citations by year
2026: 350 · 2025: 441 · 2024: 513 · 2023: 497 · 2022: 514 · 2021: 394 · 2020: 143 · 2019: 27
FWCI
201.31
Type
journal article
Language
en
Open access
Licence
www.springer.com/tdm (tdm)
Locations
  • Nature (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • Deep Blue (University of Michigan) (submittedVersion)
  • University of Michigan Library
Funders
National Cancer Institute (R01CA123088, R01CA211016, R01CA152470, R01CA205426, R01CA193136, R01CA127648, R01CA189623, R01CA214911, R35CA232097, R01CA099985, CA189623, R01CA217510, R01CA190176, CA205426, P30CA008748, P30CA046592)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
Keywords
ferroptosis, CD8+ T cells, cancer immunotherapy, lipid peroxidation, interferon-gamma, system xc-, SLC3A2, SLC7A11, cystine uptake, cysteine depletion, cysteine synthase, cancer cell death, immune checkpoint blockade, nivolumab, tumor microenvironment, antitumor immunity
MeSH terms
Nivolumab, Ferroptosis, Animals, Cysteine, Female, Humans, Immunotherapy, Interferon-gamma, Melanoma, Neoplasms, Lipid Peroxidation, Treatment Outcome, Reactive Oxygen Species, CD8-Positive T-Lymphocytes, Amino Acid Transport System y+, Fusion Regulatory Protein 1, Heavy Chain, Cell Line, Tumor, Mice, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. https://app.cochat.ai/papers/10.1038/s41586-019-1170-y
The paper
Wang, W., Green, M., Choi, J. E., Gijón, M., Kennedy, P. D., Johnson, J. K., Liao, P., Lang, X., Kryczek, I., Sell, A., Xia, H., Zhou, J., Li, G., Li, J., Li, W., Wei, S., Vatan, L., Zhang, H., Szeliga, W., . . . Zou, W. (2019). CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. https://doi.org/10.1038/s41586-019-1170-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.